medigraphic.com
ISSN 1561-2929 (Print)

2014, Number 1

<< Back Next >>

RCAN 2014; 24 (1)

Insulin sensitivity and Metabolic syndrome

Language: Spanish
References: 32
Page: 140-149
PDF size: 186.88 Kb.


ABSTRACT

Metabolic Syndrome (MS) is regarded worldwide as a global public health problem worldwide. Type 2 Diabetes (T2D) and cardiovascular diseases are the two MS complications, and represent the major leading causes of death in the working-age population. Understanding the mechanisms responsible for MS development will allow its early detection and the design of strategies for prevention of complications. It has been suggested recently that onset of MS is indeed a consequence of interactions between defects in insulin sensitivity and function of endocrine pancreas β -cell, which, in turn, become determinant factors for development of the metabolic disorders distinctive of the syndrome.


REFERENCES

  1. Meaney E, Lara Esqueda A, Ceballos Reyes GM, Asbun J, Vela A, Martínez- Marroquín Y, et al. Cardiovascular risk factors in the urban Mexican population: The FRIMEX study. Public Health 2007;121:378-84.

  2. Zimmet P, K. Alberti KGMM, Serrano- Ríos M. Una nueva definición mundial del síndrome metabólico propuesta por la Federación Internacional de Diabetes: Fundamento y resultados. Rev Esp Cardio 2005;58:1371-76.

  3. Córdova-Villalobos JA, Barriguete Meléndez JA, Lara-Esqueda A, Barquera S, Rosas-Peralta M, Hernández-Avila M, et al. Chronic noncommunicable diseases in Mexico: Epidemiologic synopsis and integral 148 Rev Cubana Aliment Nutr Vol. 24, No. 1 Baez Duarte y cols. prevention. Salud Pública Mex 2008; 50:419-427.

  4. Gutiérrez JP, Rivera-Dommarco J, Shamah-Levy T, Villalpando- Hernández S, Franco A, Cuevas-Nasu L, et al. Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales. Instituto Nacional de Salud Pública. Cuernavaca: 2012.

  5. García-García E, De la Llata-Romero M, Kaufer-Horwitz M, Tusié-Luna MT, Calzada-León R, Vázquez-Velázquez V, et al. La obesidad y el síndrome metabólico como problema de salud pública: Una reflexión. Salud Pública Mex 2008;50:530-547.

  6. Anónimo. Estadística de mortalidad 2011. Consulta interactiva de datos. INEGI Instituto Nacional de Estadística y Geografía. México: 2013.

  7. López ME, Sosa MA, María Labrousse NP. Síndrome Metabólico. Revista de Posgrado de la VIa Cátedra de Medicina 2007;174:12-15.

  8. Asociación Nacional de Cardiólogos de México. Recomendaciones para el diagnóstico, estratificación del riesgo cardiovascular, prevención y tratamiento del síndrome metabólico. Rev Mex Cardiol 2006;17:3-61.

  9. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: Modulation by nutrients and inflammation. J Clin Invest 2008;118:2992-3002.

  10. Facchini FS, Hua N, Abbasi F, Reaven GM. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 2001;86:3574-8.

  11. Hamilton MT, Hamilton DG, Zderic TW. The role of low energy expenditure and sitting on obesity, metabolic syndrome, Type 2 diabetes, and cardiovascular disease. Diabetes 2007; 56:2655-67.

  12. González-Chávez A, Malanco- Hernández LM, Sánchez-Zúñiga MJ, Elizondo Argueta S, Navarro JE, Rosillo R. Inflamación y resistencia a la insulina: Mecanismos para el desarrollo de la disfunción endotelial y aterosclerosis. Rev Mex Cardiol 2006;17:71-82.

  13. González-Chávez A, Simental L, Elizondo-Argueta S, Sánchez J, Gutiérrez Salgado J, Guerrero Romero F. Prevalencia del síndrome metabólico entre adultos mexicanos no diabéticos, usando las definiciones de la OMS, NCEP-ATP IIIa e IDF. Rev Med Hosp Gen Mex 2008;71:11-19.

  14. González-Chávez A, Amancio-Chassin O, Islas-Andrade S, Revilla-Monsale C, Hernández M, Lara-Esqueda A, et al. Factores de riesgo cardiovascular asociados a obesidad abdominal en adultos aparentemente sanos. Rev Med Inst Mex Seguro Soc 2008;46:273-9.

  15. Kahn SE, Prigeon RL, Schwartz RS, Fujimoto WY, Knopp RH, Brunzell JD, Porte D. Obesity, body fat distribution, insulin sensitivity and islet β-cell function as explanations for metabolic diversity. J Nutr 2001;131:354S-360S.

  16. Weigensberg MJ, Ball GDC, Shaibi GQ, Cruz ML, Goran MI. Decreased β- cell function in overweight Latino children with impaired fasting glucose. Diabetes Care 2005;28:2519-24.

  17. Baez-Duarte BG, Sánchez-Guillén MC, Pérez-Fuentes R, Zamora-Ginéz I, León-Chávez BA, Revilla-Monsalve C, Islas-Andrade S. β-cell function is associated with metabolic syndrome in Mexican subjects. Diabet Metab Syndr Obes 2010:3:1-9.

  18. Chen H, Sullivan G, Quon MJ. Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. Diabetes 2005;54:1914-25. Resistencia a la insulina y Síndrome metabólico Rev Cubana Aliment Nutr Vol. 24, No. 1 149

  19. Sierra-Johnson J, Johnson BD, Allison TG, Bailey KR, Schwartz GL, Turner S T. Correspondence between the adult Treatment Panel III criteria for metabolic Syndrome and insulin resistance. Diabetes Care 2006; 29:668-72.

  20. Torrens JI, Skurnick J, Davidow AL, Korenman SG, Santoro N, Soto-Greene M, et al. Ethnic differences in insulin sensitivity and beta-cell function in premenopausal or early perimenopausal women without diabetes: The Study of Women´s Health Across the Nation (SWAN). Diabetes Care 2004;27: 354-61.

  21. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes 1995;44:1386-91.

  22. Bastarrachea RA, Fuenmayor R, Brajkovich I, Comuzzie AG. Entendiendo las causas de la obesidad a través de la biología celular del adipocito Rev Venez Endocrinol Metab 2005;3:20-9.

  23. Sironi AM, Gastaldelli A, Mari A, Ciociaro D, Positano V, Buzzigoli E, et al. Visceral fat in hipertensión: influence on insulin resistance and β- cell function. Hypertension 2004;44: 127-33.

  24. Santana Porbén S. Las adipocitoquinas en la génesis y evolución del Síndrome metabólico. RCAN Rev Cubana Aliment Nutr 2010;20:304-17.

  25. Zi-Lun L, Woollard JR, Ebrahimi B, Crane JA, Jordan KL, Lerman A, et al. Transition from obesity to metabolic syndrome is associated with altered myocardial autophagy and apoptosis. Aterioscler Thromb Vasc Biol 2012;32: 1132-41.

  26. Smith GR, Shanley DP. Computational modeling of the regulation of insulin signaling by oxidative stress. BMC Systems Biology 2013;7:1-19.

  27. Rains JL, Jain SK. Oxidative stress, insulin signaling and diabetes. Free Radic Biol Med 2011;50:567-75.

  28. Styskal JL, Van-Remmen H, Richardson A, Salmon AB. Oxidative stress and diabetes: What can we learn about insulin resistance from antioxidant mutant mouse models? Free Radic Biol Med 2012;52:46-58.

  29. Ye J. Mechanisms of insulin resistance in obesity. Front Med 2013;7:14-24.

  30. Pansuria M, Xi H, Li L, Yang XF, Wang H. Insulin resistance, metabolic stress and atherosclerosis. Front Biosci (Scholar Edition) 2012;4:916-31.

  31. Maytin M, Leopold J, Loscalzo J. Oxidant stress in the vasculature. Curr Atheroscler Rep 1999;1:156-64.

  32. Aroor AR, Mandavia CH, Sowers JR. Insulin resistance and heart failure: molecular mechanisms. Heart Fail Clin 2012;8:609-17 (Scholar Edition) 2012;4:916-31.




2020     |     www.medigraphic.com